ArticleArchives of disease in childhood1993
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis.
Article in Archives of disease in childhood, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 105 citations in OpenAlex.
- Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021Trial
- A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2014Trial
- Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.Archives of disease in childhood · 1997Trial
- Dysregulation of the Arachidonic Acid Pathway in Cystic Fibrosis: Implications for Chronic Inflammation and Disease Progression.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis.American journal of respiratory and critical care medicine · 2020Article
- Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease.EBioMedicine · 2017Article
- An Innovative High-Throughput Screening Approach for Discovery of Small Molecules That Inhibit TNF Receptors.SLAS discovery : advancing life sciences R & D · 2017Article
- Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis.Clinical and translational science · 2015Article
- Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function.World journal of critical care medicine · 2015Review
- The Role of Serine Proteases and Antiproteases in the Cystic Fibrosis Lung.Mediators of inflammation · 2015Review
- Antiproteases as therapeutics to target inflammation in cystic fibrosis.The open respiratory medicine journal · 2010Article
- Estrogen receptor-alpha as a drug target candidate for preventing lung inflammation.Endocrinology · 2010Article
- Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.The Clinical biochemist. Reviews · 2009Article
- Update on gene modifiers in cystic fibrosis.Current opinion in pulmonary medicine · 2008Review
- Sputum biomarkers of inflammation in cystic fibrosis lung disease.Proceedings of the American Thoracic Society · 2007Review
- Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?Naunyn-Schmiedeberg's archives of pharmacology · 2006Review
- Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship.Clinical and experimental immunology · 2005Article
- Cystic fibrosis modifier genes.Journal of the Royal Society of Medicine · 2005Review
- Monitoring inflammation in CF. Cytokines.Clinical reviews in allergy & immunology · 2002Review
- Use of modulators of airways inflammation in patients with CF.Clinical reviews in allergy & immunology · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is postulated that a vigorous host inflammatory response in the cystic fibrosis lung contributes to lung injury. Tumour necrosis factor-alpha (TNF-alpha) may play a part in that process and in the generation of leukotrienes. Therefore, the relationships between sputum TNF-alpha, leukotriene concentration, and lung function abnormalities in 16 children with cystic fibrosis were investigated. Each subject provided sputum samples and performed spirometry. TNF-alpha was measured by enzyme linked immunosorbent assay; individual leukotrienes were separated using high performance liquid chromatography and quantified by radioimmunoassay. The geometric mean concentration of TNF-alpha was 129.7 pg/ml and 95% confidence interval 48.2 to 348.3. Mean (SEM) leukotriene B4 (LTB4) was 97.8 (22.9) pmol/g and total cysteinyl leukotrienes were 60.9 (14.8) pmol/g. Mean (SD) forced expiratory volume in one second (FEV1) of the group was 53 (15)% of predicted and forced vital capacity (FVC) was 65 (14)% of predicted. There was a significant positive correlation between TNF-alpha and both LTB4 and the total cysteinyl leukotriene sputum content. An inverse relationship existed between TNF-alpha and FEV1 and FVC. Moreover, a negative correlation was observed between sputum LTB4 and FEV1 and FVC. These results suggest that TNF-alpha and the leukotrienes may participate in the airways inflammation and airflow obstruction observed in cystic fibrosis subjects and support the hypothesis that TNF-alpha upregulates the 5-lipoxygenase pathway in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.